Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug 22;318(8):713-720.
doi: 10.1001/jama.2017.10565.

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

G Michael Felker  1 , Kevin J Anstrom  1 , Kirkwood F Adams  2 , Justin A Ezekowitz  3 , Mona Fiuzat  1 , Nancy Houston-Miller  4 , James L Januzzi Jr  5 , Daniel B Mark  1 , Ileana L Piña  6 , Gayle Passmore  1 , David J Whellan  7 , Hongqiu Yang  1 , Lawton S Cooper  8 , Eric S Leifer  8 , Patrice Desvigne-Nickens  8 , Christopher M O'Connor  1   9
Affiliations
Randomized Controlled Trial

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

G Michael Felker et al. JAMA. .

Abstract

Importance: The natriuretic peptides are biochemical markers of heart failure (HF) severity and predictors of adverse outcomes. Smaller studies have evaluated adjusting HF therapy based on natriuretic peptide levels ("guided therapy") with inconsistent results.

Objective: To determine whether an amino-terminal pro-B-type natriuretic peptide (NT-proBNP)-guided treatment strategy improves clinical outcomes vs usual care in high-risk patients with HF and reduced ejection fraction (HFrEF).

Design, settings, and participants: The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) study was a randomized multicenter clinical trial conducted between January 16, 2013, and September 20, 2016, at 45 clinical sites in the United States and Canada. This study planned to randomize 1100 patients with HFrEF (ejection fraction ≤40%), elevated natriuretic peptide levels within the prior 30 days, and a history of a prior HF event (HF hospitalization or equivalent) to either an NT-proBNP-guided strategy or usual care.

Interventions: Patients were randomized to either an NT-proBNP-guided strategy or usual care. Patients randomized to the guided strategy (n = 446) had HF therapy titrated with the goal of achieving a target NT-proBNP of less than 1000 pg/mL. Patients randomized to usual care (n = 448) had HF care in accordance with published guidelines, with emphasis on titration of proven neurohormonal therapies for HF. Serial measurement of NT-proBNP testing was discouraged in the usual care group.

Main outcomes and measures: The primary end point was the composite of time-to-first HF hospitalization or cardiovascular mortality. Prespecified secondary end points included all-cause mortality, total hospitalizations for HF, days alive and not hospitalized for cardiovascular reasons, the individual components on the primary end point, and adverse events.

Results: The data and safety monitoring board recommended stopping the study for futility when 894 (median age, 63 years; 286 [32%] women) of the planned 1100 patients had been enrolled with follow-up for a median of 15 months. The primary end point occurred in 164 patients (37%) in the biomarker-guided group and 164 patients (37%) in the usual care group (adjusted hazard ratio [HR], 0.98; 95% CI, 0.79-1.22; P = .88). Cardiovascular mortality was 12% (n = 53) in the biomarker-guided group and 13% (n = 57) in the usual care group (HR, 0.94; 95% CI; 0.65-1.37; P = .75). None of the secondary end points nor the decreases in the NT-proBNP levels achieved differed significantly between groups.

Conclusions and relevance: In high-risk patients with HFrEF, a strategy of NT-proBNP-guided therapy was not more effective than a usual care strategy in improving outcomes.

Trial registration: clinicaltrials.gov Identifier: NCT01685840.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures

GM Felker: Dr. Felker reports research support from NIH, AHA, Roche Diagnostics, Amgen, Novartis, Merck; consulting for Novartis, Amgen, Medtronic, GSK, BMS, Myokardia, Stealth

KJ Anstrom: Dr. Anstrom reports no relevant disclosures.

KF Adams: Dr. Adams reports research funding for Roche Diagnostics; consulting for Roche Diagnostics.

JA Ezekowitz: Dr. Ezekowitz reports grants or honoraria from Novartis, Servier, Bayer, Merck, Trevena, Amgen, Canadian Institutes of Health Research, National Institutes of Health, and the Heart and Stroke Foundation of Canada.

M Fiuzat: Dr. Fiuzat reports research funding from Roche Diagnostics.

N Houston-Miller: Ms. Houston-Miller reports no relevant disclosures.

JL Januzzi: Dr. Januzzi reports received grant support from Siemens, Singulex and Prevencio, consulting income from Roche Diagnostics, Critical Diagnostics, Sphingotec, Phillips, and Novartis, and participates in clinical endpoint committees/data safety monitoring boards for Abbvie, Pfizer, Novartis, Amgen, Janssen, and Boehringer Ingelheim. Dr. Januzzi is supported in part by the Hutter Family Professorship in Cardiology.

DB Mark: Dr. Mark reports consulting for Medtronic, CardioDx, and St. Jude Medical; research grants from Eli Lilly, Medtronic, Bristol Myers Squibb, AstraZeneca, Merck & Company, Oxygen Therapeutics, and Gilead.

IL Piña: Dr. Piña reports no relevant disclosures.

G Passmore: Ms. Passmore reports no relevant disclosures.

DJ Whellan: Dr. Whellan reports no relevant disclosures.

H Yang: Dr. Yang reports no relevant disclosures.

LS Cooper: Dr. Cooper reports no relevant disclosures.

ES Liefer: Dr. Liefer reports no relevant disclosures.

P Desvigne-Nickens: Dr. Desvigne-Nickens reports no relevant disclosures.

CM O’Connor: Dr. O’Connor reports grant funding and consulting for Roche Diagnostics.

Figures

Figure 1
Figure 1. Flowchart of Patient Accountability
This figure displays a flowchart of patient accountability, from the initial randomized patients through the number of patients who completed the study or withdrew from both the biomarker-guided and usual care groups. Data on the number of patients screened for eligibility are not available. Abbreviations: VAD, ventricular assist device
Figure 2
Figure 2. Primary Endpoint (Heart failure hospitalization or CV mortality) and All-Cause Mortality
Kaplan-Meier curves for: A) primary endpoint (heart failure hospitalization or CV mortality); and B) all-cause mortality. Abbreviations: CV, cardiovascular; HF, heart failure
Figure 2
Figure 2. Primary Endpoint (Heart failure hospitalization or CV mortality) and All-Cause Mortality
Kaplan-Meier curves for: A) primary endpoint (heart failure hospitalization or CV mortality); and B) all-cause mortality. Abbreviations: CV, cardiovascular; HF, heart failure
Figure 3
Figure 3. Change in NT-proBNP Levels
NT-proBNP levels between the groups over time. Abbreviations: NT-proBNP, amino-terminal pro–B-type natriuretic peptide. B-guided, Biomarker guided therapy
See this image and copyright information in PMC

Comment in

References

    1. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294(10):1240–1247. - PubMed
    1. Fonarow GC, Albert NM, Curtis AB, et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) Circulation. 2010;122(6):585–596. - PubMed
    1. Januzzi JL, Jr, Sakhuja R, O'Donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166(3):315–320. - PubMed
    1. Anand IS, Fisher LD, Chiang YT, et al. Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) Circulation. 2003;107(9):1278–1283. - PubMed
    1. Masson S, Latini R, Anand IS, et al. Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial) J Am Coll Cardiol. 2008;52(12):997–1003. - PubMed

Publication types

Associated data